Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer

Drug-tolerant insurgents

Some cancer cells that become tolerant to a drug remain resistant even after its withdrawal, yet these cells eventually become sensitive to the drug again. The underlying molecular mechanism is unusual.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Evolution and 'de-evolution' of drug resistance.

References

  1. Nowell, P. C. Science 194, 23–28 (1976).

    Google Scholar 

  2. Weinberg, R. A. The Biology of Cancer Ch. 11 (Garland Science, 2006).

    Google Scholar 

  3. Stratton, M. R. et al. Nature 458, 719–724 (2009).

    Google Scholar 

  4. Vogelstein, B. et al. N. Engl. J. Med. 319, 525–532 (1988).

    Google Scholar 

  5. Hanahan, D. & Weinberg, R. A. Cell 100, 57–70 (2000).

    Google Scholar 

  6. Greaves, M. Hematology 3–12 (2009).

  7. Sawyers, C. L. Nature Med. 13, 1144–1145 (2007).

    Google Scholar 

  8. Redmond, K. M. et al. Front. Biosci. 13, 5138–5154 (2008).

    Google Scholar 

  9. Sharma, S. V. et al. Cell 141, 69–80 (2010).

    Google Scholar 

  10. Benevolenskaya, E. V. et al. Mol. Cell 18, 623–635 (2005).

    Google Scholar 

  11. Dhar, N. & McKinney J. D. Curr. Opin. Microbiol. 10, 30–38 (2007).

    Google Scholar 

  12. Cara, S. & Tannock, I. F. Ann. Oncol. 12, 23–27 (2001).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Paul Workman is an employee of and Jon Travers a graduate student at the Institute of Cancer Research (ICR), which operates a rewards to inventors scheme. The ICR has an actual or potential commercial interest in inhibitors of chromatin-modifying enzymes, including histone deacetylases and histone demethylases. P.W. is a founder of, Scientific Advisory Board chair of, consultant to, non-executive director of and member of the Board of Directors of Chroma Therapeutics.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Workman, P., Travers, J. Drug-tolerant insurgents. Nature 464, 844–845 (2010). https://doi.org/10.1038/464844a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/464844a

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing